FBLG Live signals | Maximize Profits with Getagraph.com

SELL 134796 min ago

@ $12.67

Issued: 13 Feb 2024 @ 14:24

Return: -6.90%

Previous signal: Feb 6 - 13:27

Previous signal: Buy

Return: 11.47 %

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Stats
Today's Volume	68 805.00
Average Volume	68 500.00
Market Cap	386.09M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0610 (0.52%)

Volume Correlation

Long: 0.19 (neutral)

Short: 0.38 (neutral)

Signal:(59.383) Neutral

FibroBiologics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FibroBiologics, Inc. Correlation - Currency/Commodity

0.74
( moderate )

0.78
( moderate )

0.00
( neutral )

-0.18
( neutral )

0.64
( weak )

-0.39
( neutral )

Financial Reports:

No articles found.

FibroBiologics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

FibroBiologics, Inc.

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.